SGLT2 inhibitors and GLP-1 receptor agonists lower cardiovascular risk in type 2 diabetes, but a recent review suggests that ...

The company also shared Phase 3 data from the ACHIEVE-1 trial of orforglipron, its oral obesity drug, which met A1C reduction targets and showed dose-dependent weight loss over 40 weeks.

Blockbuster weight-loss shots like Ozempic, Wegovy and Victoza may have an unexpected side effect impacting as many as 47million Americans, a new study from researchers in Italy found.

A target A1C of 7% is a common goal for adults with diabetes, helping reduce long-term complications and improve blood sugar ...

GLP-1 receptor agonists, a class of drug used to treat type 2 diabetes, likely trump the widely prescribed metformin for ...

Some common medications can lead to vitamin and mineral deficiencies. Learn which drugs can interact in this way.

A new study reports that GLP-1 medications may improve low testosterone in men with obesity or type 2 diabetes. The findings ...

Once-weekly IcoSema, a combination therapy of basal insulin icodec and semaglutide, achieves a noninferior reduction in A1c levels compared with basal-bolus therapy in adults with T2D.

Compared with other antidiabetic drugs, semaglutide is associated with a lower risk for Alzheimer disease-related dementia in patients with type 2 diabetes.

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped participants in a phase 2 clinical trial shed about 20% of their body ...

Women with diabetes who were overweight or had obesity lost more weight and had greater odds of diabetes remission when swapping diet soda for water.